Examination of the protective efficacy for vein thromboembolism (VTE) and safety of enoxaparin sodium after the abdominal surgery

Examination of the protective efficacy for vein thromboembolism (VTE) and safety of enoxaparin sodium after the abdominal surgery - Examination of enoxaparin sodium after the abdominal surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009598

Enrollment

100

Registered

2012-12-25

Start date

2012-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Case of surgery targeted for the VTE prevention

Exclusion criteria

Exclusion criteria: 1) The patient who bleeds 2 thrombocytopenia 3) Patient having the complications that may bleed(including a gastrointestinal ulcer, gastrointestinal diverticulitis, colitis, acute bacterial endocarditis, seriously ill high blood pressure, severe diabetes, the DIC). 4) Patient with impaired severe liver function 5) Sensitivity to danaparoid, heparin, low molecular weight heparin. 6) The patient who has the past of cerebral hemorrhage 7) The patient who received the operation of the central nervous system or ophthalmology within three months before registration of the final examination

Design outcomes

Primary

Measure	Time frame
Outbreak frequency of symptomatic PTE or VTE judged by imaging study	—

Countries

Japan

Outcome results